FDA approves reduced monitoring time for first two IMDELLTRA doses
Amgen said the FDA approved an update to IMDELLTRA that reduces the monitoring time required for the first two doses, supporting broader access in community settings for people with extensive-stage small cell lung cancer.
Story updates
01:01:42 PM UTC
SquawkNews
FDA approved an update to Amgen’s IMDELLTRA label, reducing monitoring for the first two infusions to 6—8 hours from 22—24 hours, with next-day assessments retained.Material DetailsContext by AI AnalystThis is an incremental but commercially relevant label optimization that reduces barriers to IMDE…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.